Get the Stockscreener App
13.78
1.17%
0.16
Arcturus Therapeutics Holdings Inc stock is traded at $13.78, with a volume of 172.65K.
It is up +1.17% in the last 24 hours and up +6.00% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
See More
Previous Close:
$13.62
Open:
$13.66
24h Volume:
172.65K
Relative Volume:
0.40
Market Cap:
$349.86M
Revenue:
$157.75M
Net Income/Loss:
$-29.73M
P/E Ratio:
-11.88
EPS:
-1.16
Net Cash Flow:
$-21.00M
1W Performance:
-4.37%
1M Performance:
+6.00%
6M Performance:
-23.19%
1Y Performance:
-37.16%
1-Day Range:
$13.44
$13.94
1-Week Range:
$12.65
$14.58
52-Week Range:
$8.04
$25.88
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
13.78 | 349.86M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-28-25 | Initiated | BTIG Research | Buy |
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Bank of America Corp DE - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Analysts Offer Predictions for ARCT FY2026 Earnings - Defense World
Two Sigma Investments LP Increases Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
(ARCT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Squarepoint Ops LLC Sells 22,752 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics Holdings Inc (ARCT) Is A Good Stock To Invest In - Stocksregister
Arcturus Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Transcript : Arcturus Therapeutics Holdings Inc.Shareholder/Analyst Call - marketscreener.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Position Increased by Ameriprise Financial Inc. - Defense World
Nuveen Asset Management LLC Sells 10,221 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
BNP Paribas Financial Markets Sells 13,093 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet - sharewise
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Purchased by Deutsche Bank AG - Defense World
Arcturus Therapeutics to Attend Upcoming Investor Conferences - Business Wire
Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at Scotiabank - Defense World
Scotiabank Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Sector Outperform Recommendation - Nasdaq
When the Price of (ARCT) Talks, People Listen - news.stocktradersdaily.com
Scotiabank Initiates Coverage on Arcturus Therapeutics (ARCT) | - GuruFocus
Arcturus Therapeutics (ARCT) Receives Positive Outlook with Potential Upside | ARCT Stock News - GuruFocus
Scotiabank Initiates Arcturus Therapeutics at Outperform - marketscreener.com
Man Group plc Sells 4,168 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics’ SWOT analysis: mRNA innovator’s stock faces pivotal year - Investing.com India
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of “Buy” by Brokerages - Defense World
Wall Street Zen Upgrades Arcturus Therapeutics (NASDAQ:ARCT) to “Hold” - Defense World
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A 481% Upside Potential Amidst Biotech Innovations - DirectorsTalk Interviews
Northern Trust Corp Has $4.35 Million Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Trend Tracker for (ARCT) - news.stocktradersdaily.com
Wells Fargo & Company Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $45.00 - Defense World
Arcturus signals extended cash runway into 2028 with strategic shift toward CF and OTC mRNA therapeutics - MSN
FY2025 EPS Estimates for ARCT Raised by Cantor Fitzgerald - The AM Reporter
Leerink Partnrs Analysts Raise Earnings Estimates for ARCT - Defense World
Price T Rowe Associates Inc. MD Increases Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
William Blair Brokers Boost Earnings Estimates for ARCT - Defense World
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade - Yahoo Finance
Canaccord Genuity Group Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - Defense World
Arcturus Therapeutics (ARCT): Wells Fargo Maintains Rating, Lowe - GuruFocus
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2025 Earnings Call Transcript - Insider Monkey
Wells Fargo Adjusts Price Target for Arcturus Therapeutics (ARCT) | ARCT Stock News - GuruFocus
Arcturus Therapeutics (ARCT) Set for Potential Upside with Citi's Confidence | ARCT Stock News - GuruFocus
Arcturus Therapeutics Holdings Inc earnings missed by $4.11, revenue fell short of estimates - Investing.com Nigeria
Canaccord Genuity Maintains Buy Rating on Arcturus Therapeutics (ARCT) | ARCT Stock News - GuruFocus
Demystifying Arcturus Therapeutics: Insights From 7 Analyst Reviews - Benzinga
Arcturus Therapeutics (ARCT) Price Target Revised by Canaccord | - GuruFocus
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings: EPS - GuruFocus
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call Highlights: Strategic Focus and ... - Yahoo Finance
Arcturus Therapeutics stock jumps 7% despite Q1 loss By Investing.com - Investing.com India
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call - GuruFocus
Arcturus Therapeutics Reports Q1 2025 Financial Update - TipRanks
Arcturus Therapeutics (ARCT) Sees Strong Progress with Pipeline Programs - GuruFocus
Earnings call transcript: Arcturus Therapeutics Q1 2025 sees revenue drop, stock rises - Investing.com
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):